Amedisys (AMED) Tops Q1 EPS by 11c; Offers FY22 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Amedisys Reports First Quarter 2022 Financial Results and Reaffirms 2022 Guidance
April 27, 2022 4:05 PM EDTBATON ROUGE, La., April 27, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2022.
Three-Month Periods Ended March 31, 2022 and 2021
Net service revenue increased $8.2Â million to $545.3Â million compared to $537.1Â million in 2021.Net income attributable to Amedisys, Inc. of $31.7Â million compared to $49.9Â million in 2021.Net income attributable to Amedisys, Inc. per diluted share of $0.97 compared to $1.50 in 2021.Adjusted Quarterly Results*
Adjusted EBITDA of $66.3Â million compared to $78.6Â million in 2021.Adjusted net income attributable to Amedisys, Inc. of $40.1Â million compared to $51.1Â million in... More